Drugs / LYNC-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07505030 | May 2026 → Mar 2027 expected | ulcerative colitis | LyncBio Therapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LYNC-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07505030 ↗ |
| Route | Intravenous | “Administered as a single dose via intravenous infusion” NCT07505030 ↗ |